You're going to get questions about this one...
"GlaxoSmithKline's recombinant zoster vaccine (adjuvanted) (Shingrix) has been approved in Canada for the prevention of herpes zoster (shingles) in people aged 50 years and older."
Okay, so how is it different from Zostavax II?
"The approval of Shingrix in Canada is based on efficacy data collected in more than 37,000 people which demonstrated an efficacy rate against shingles greater than 90%,and this is independent from age (≥50 and ≥70 years of age), as well as a sustained efficacy over the entire follow-up period. "
Compared to Zostavax II:
"Overall vaccine efficacy was 51.3% for HZ incidence and 66.5% for PHN."
News that has been personally selected by the Editorial team.